hPCL3s Promotes Hepatocellular Carcinoma Metastasis by Activating β-Catenin Signaling

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Two isoforms of human Polycomb-like protein 3 (hPCL3) exist, with the short isoform (hPCL3s) primarily in the cytoplasm.
• The function of cytoplasmic hPCL3s in cancer progression was previously unknown.

Purpose of the Study:

• To investigate the role of cytoplasmic hPCL3s in hepatocellular carcinoma (HCC) development and metastasis.
• To elucidate the molecular mechanisms by which hPCL3s influences HCC progression.

Main Methods:

• Analysis of hPCL3s expression in clinical HCC samples and correlation with clinical features.
• In vitro assays to assess the effect of hPCL3s on HCC cell migration, invasion, and metastasis.
• Investigation of hPCL3s interaction with the β-catenin destruction complex and downstream signaling pathways (β-catenin/T-cell factor and IL6).
• In vivo studies using a HCC mouse model with forced hPCL3s expression.

Main Results:

• hPCL3s is upregulated in HCC and correlates with adverse clinical features.
• hPCL3s enhances HCC cell migration, invasion, and metastasis.
• hPCL3s inhibits β-catenin degradation by interacting with its cytoplasmic destruction complex, activating β-catenin/T-cell factor signaling.
• IL6 mediates the motility-promoting effects of hPCL3s.
• Forced hPCL3s expression in a mouse model promotes tumorigenesis and metastasis.

Conclusions:

• hPCL3s functions as an oncogene in HCC, promoting metastasis.
• hPCL3s activates the β-catenin/IL6 signaling axis, driving HCC progression and metastasis.